Oncology Medical News about platinum-refractory or-resistant ovarian cancer;canfosfamide;pegylated liposomal doxorubicin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
European Journal of Cancer, 06/15/09

Vergote I et al. - Canfosfamide HCl (CAN; a glutathione analogue prodrug that is activated by glutathione S-transferase P1-1 and induces apoptosis) was well tolerated in pts with platinum-refractory or -resistant ovarian cancer (OC).

Methods

Pts with platinum-refractory or -resistant OC who had progressed on second-line therapy with pegylated liposomal doxorubicin (PLD) or topotecan (TOPO), were randomized to:
- CAN 1000 mg/m2 IV q 3 weeks or
- Either PLD 50 mg/m2 IV q 4 wks or TOPO 1.5 mg/m2 IV d1-5 q 3 wks

Results

461 pts were randomised after stratification for ECOG performance status, prior therapy, and bulky (>5 cm) disease
Groups were well balanced
In the control arm 58% and 42% were treated with PLD and TOPO, respectively
CAN was well tolerated with the most common grade 3-4 toxicities of 5% anaemia, 4% neutropaenia (no febrile neutropaenia), 4% thrombocytopaenia, and 7% vomiting
PFS and OS were higher in the control arm
In a subgroup analysis PFS and OS were higher with PLD than with TOPO

<< Previous
Population pharmacokinetics of erlotinib and its...

Next >>
Involvement of Nrf2 activation in resistance to 5-fluorouracil in...